Drug Trial Radar · NCT04968912
A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
163
Actual
Start
Sep 21, 2021
Primary completion
Oct 23, 2023
Study completion Nov 30, 2023
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jul 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of nipocalimab in participants with primary Sjogren's syndrome (pSS) versus placebo.
Conditions
- Sjogren's Syndrome
Interventions
PlaceboOther
Placebo infusion will be administered intravenously.
NipocalimabDrug
Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.
Standard of Care TreatmentDrug
Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Clinical European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (clinESSDAI) Score at Week 24Time frame: Baseline (Week 0), Week 24
Locations
69 sites in 10 countries. Site status is shown where the registry gives one.
Anniston Medical Clinic
Anniston, Alabama
Arizona Arthritis and Rheumatology Research PLLC
Glendale, Arizona
Arizona Arthritis & Rheumatology Research, PLLC
Mesa, Arizona
St. Jude Heritage Medical Group
Fullerton, California
Inland Rheumatology Clinical Trials, Inc.
Upland, California
Colorado Arthritis Associates
Denver, Colorado
Denver Arthritis Clinic
Denver, Colorado
Rheumatology Associates Of South Florida
Boca Raton, Florida
Bay Area Arthritis and Osteoporosis
Brandon, Florida
Centre for Rheumatology, Immunology and Arthritis
Fort Lauderdale, Florida
University of Florida Health Jacksonville
Jacksonville, Florida
Omega Research Consultants
Orlando, Florida
Clinical Investigation Specialists
Gurnee, Illinois
University of Iowa Hospitals and Clinics
Iowa City, Iowa
University of Kansas Medical Center
Kansas City, Kansas
St. Paul Rheumatology P A
Eagan, Minnesota
North Mississippi Medical Clinics
Tupelo, Mississippi
PMG Research of Salisbury
Salisbury, North Carolina
Altoona Center For Clinical Research
Duncansville, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania
Columbia Arthritis Center
Columbia, South Carolina
West Tennessee Research Institute
Jackson, Tennessee
Dr. Ramesh Gupta
Memphis, Tennessee
Austin Regional Clinic
Austin, Texas
Trinity Clinical Research, LLC
Carrollton, Texas
CHU de Grenoble Hopital Albert Michallon
La Tronche, France
Centre Hospitalier Le Mans
Le Mans, France
Hopital Saint Joseph
Marseille, France
Hopital Pitie Salpetriere
Paris, France
CHRU Hôpital de Hautepierre
Strasbourg, France
Charite Universitaetsmedizin Berlin
Berlin, Germany
Uniklinik Köln
Cologne, Germany
Universitatsklinikum Carl Gustav Carus Dresden
Dresden, Germany
Hamburger Rheuma Forschungszentrum II
Hamburg, Germany
medius KLINIK KIRCHHEIM
Kirchheim unter Teck, Germany
Universitatsklinikum Tubingen
Tübingen, Germany
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Presidio Spedali Civili
Brescia, Italy
P.O. Vittorio Emanuele Azienda Ospedaliero Universitaria 'Policlinico Vittorio Emanuele'
Catania, Italy
IRCCS Ospedale San Raffaele
Milan, Italy
Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
Palermo, Italy
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.